Helping you access curative therapies for liver cancer patients
|
|
- Timothy Gibbs
- 6 years ago
- Views:
Transcription
1 Metastatic colorectal cancer (mcrc) Helping you access curative therapies for liver cancer patients Biocompatibles Excellence in Interventional Oncology Biocompatibles UK Ltd is a BTG International group company
2 DEBIRI withdc Bead is a liver-directed therapy which is well tolerated in colorectal patients with liver-dominant metastases 1,2 DEBIRI with DC Bead has been shown to offer the potential to downstage liver cancer patients to curative therapies by improving tumour response and delaying progression. 1,2 By protecting healthy liver, DEBIRI with DC Bead may help reduce hepatic insufficiency, specifically steatohepatitis, and reduce morbidity at resection. 2,3,4 DEBIRI with DC Bead : As a concomitant therapy with systemic chemotherapy in chemo-naïve patients As a neoadjuvant therapy in chemo-naïve patients prior to resection Giving mcrc patients more treatment options
3 Downstaging therapy DEBIRI withdc Bead concomitant with systemic therapy in chemo-naïve patients DEBIRI in Treatment of Chemo-Naïve Unresectable mcrc with Concomitant Systemic Fluorouracil and Oxaliplatin [FOLFOX]: Pharmacokinetics and Phase 1 Trial 1 PI: Robert Martin MD, University of Louisville School of Medicine, KY, USA Downstaging: 40% (4/10) downstaged to resection Pharmacokinetics: - Minimal detectable levels of CPT-11 and SN-38 at 24 hours after DEBIRI - No dose-limiting toxicity - No irinotecan-related systemic effects Median overall survival: 15.2 months Overall pathological response: >95% (resected specimens) Inclusion Criteria Chemo-naïve for metastatic disease One lesion >1cm (mrecist) Liver-dominant mcrc ( 80% tumour burden confined to liver) <60% liver replacement by tumour ECOG status 2 Life expectancy 3 months Adequate haematologic and liver function Response (mrecist) Liver-specific response 100% 100% 100% 100% 100% 90% 90% 80% 80% 70% 60% 60% 50% 50% 40% 30% 20% 10% 0% 3 Months 6 Months 9 Months 12 Months Martin RCG et al. J Gastrointest Surg 16 (2012): Overall response We demonstrated enhanced response rates, without added systemic effects and the ability to downstage patients to hepatic resection. Schema n=10 Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 FOLFOX DEBIRI FOLFOX DEBIRI FOLFOX FOLFOX +/ 100mg +/ 100mg +/ Break +/ Avastin Irinotecan Avastin Irinotecan Avastin Avastin
4 Neoadjuvant therapy DEBIRI withdc Bead a neoadjuvant therapy in chemo-naïve patients prior to resection Feasibility of Neoadjuvant DEBIRI with DC Bead for Resectable Liver Metastases 3 PI: Mr Graeme Poston, University Hospital Aintree, Liverpool, UK DEBIRI with DC Bead may offer: Improved response in target tissue 2,3,4 Protection of healthy liver due to targeted nature of drug delivery 2,3 Reduced risk of excessive bleeding due to sinusoidal congestion and thrombosis (systemic oxaliplatin) 3 Reduced risk of steatosis and steatohepatitis (systemic irinotecan), which can lead to post-operative liver failure and 90-day death 2,3 % Patients Pathological Response Rates after Treatment 4, % 22% 36% 59% FOLFOX/FOLFIRI DEBIRI Minor Major Complete > 50% residual cancer cells 1 to 49% residual cancer cells No residual cancer cells Pathological response 9% 17% The ability to administer effective high-dose cytotoxic irinotecan without inducing significant hepatic insufficiency, specifically steatohepatitis, is of utmost importance to hepatobiliary surgeons. Resection after neoadjuvant DEBIRI -TACE for CRLM [colorectal liver metastases] is feasible and well tolerated. Single treatment with DEBIRI -TACE resulted in tumour pathologic response similar to that seen after protracted systemic chemotherapy. Bower M et al. HPB (Oxford) 12 (2010): 31-6 Jones RP et al. J Clin Oncol 30 (2012): suppl; abstr 3613 Before DEBIRI 4 weeks after DEBIRI No DEBIRI : Viable liver tumour cells DEBIRI : Liver tumour cell death
5 Downstaging therapy DEBIRI withdc Bead a downstaging and neoadjuvant therapy in unresectable patients Surgical Downstaging and Neoadjuvant Therapy in Metastatic Colorectal Carcinoma with Irinotecan- Eluting Beads: A Multi-Institutional Study 2 PI: Matthew Bower MD, University of Louisville School of Medicine, KY, USA Downstaging: 20% (11/55) patients downstaged to resection or ablation Patient characteristics: - 30% patients were undergoing simultaneous systemic chemotherapy - Median number of lesions was 4 (range 1-20) - Median total size of target lesions was 9cm (range cm) - 50% of patients had bilobar tumour distribution Tumour Response (RECIST) 3 Months 6 Months 12 Months 18 Months Complete Response 6% 7% 6% 8% Partial Response 33% 35% 50% 83% Stable Disease 52% 54% 32% 0% Progressive Disease 9% 4% 12% 8% Inclusion Criteria Liver-dominant mcrc (>50% overall total disease burden) ECOG status <2 Life expectancy >3 months % Patients Extent of Liver Involvement % % 10% <25% 26-50% >50% Liver involvement The utilisation of precision hepatic arterial irinotecan infusion as a monotherapy or in conjunction with current systemic chemotherapy opens up multiple opportunities in optimising patients with high-risk colorectal cancer. Bower M et al. HPB (Oxford) 12 (2010): 31-6 Giving mcrc patients more treatment options
6 Surgical Oncology References: 1 Martin RCG, Scoggins CR, Tomalty D et al. J Gastrointest Surg 16 (2012): Bower M, Metzger T, Robbins K et al. HPB (Oxford) 12 (2010): Poston G, Presentation (Satellite Symposium), IHPBA Paris, France, 3 July Jones RP, Malik HZ, Fenwick SW et al. J Clin Oncol 30, 2012 (suppl; abstr 3613) 5 Blazer DG, Kishi Y, Maru DM et al. J Clin Oncol 26 (2008): Important Safety Information DC Bead Indications: DC Bead is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug DC Bead is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mcrc) For full instructions for use, please refer to: DC Bead M1 Indications: DC Bead M1 is primarily intended as an embolic agent for the treatment of malignant hypervascularised tumour(s) DC Bead M1 is compatible with irinotecan, which can be loaded prior to embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the mcrc after embolisation DC Bead M1 is compatible with doxorubicin, which can be loaded prior to embolisation and then, as a secondary action, elute a local, controlled and sustained dose to the tumour after embolisation For full instructions for use, please refer to: Both products and/or all indications may not be available in your territory. DC Bead and DC Bead M1 are not cleared by the FDA for sale or distribution in the USA. DC Bead and DC Bead M1 are manufactured by Biocompatibles UK Ltd. Cautions: DC Bead and DC Bead M1 Embolisation with DC Bead/DC Bead M1 should only be performed by a physician with appropriate interventional occlusion training in the region intended to be embolised Do not use if the vial or packaging appear damaged Ensure that DC Bead/DC Bead M1 is an appropriate size for the intended vasculature Consider upsizing to a larger size of DC Bead in the presence of AV shunts or if angiographic evidence of embolisation does not appear quickly during delivery Consideration should be given to Tc99m-MAA scanning if there is suspicion of AV shunting Cautions: Irinotecan-loaded DC Bead and DC Bead M1 On addition of non-ionic contrast/water mixture to irinotecan-loaded beads, some irinotecan will be eluted over time. If the beads are not used immediately, up to 10mg irinotecan may be present in the contrast/water mixture. If this occurs, a small dose of irinotecan may be available systemically at time of delivery Do not use irinotecan-loaded beads with contrast agents containing salts (e.g. Calcium chloride) The maximum amount of irinotecan that can be loaded is 100mg irinotecan per vial of DC Bead/DC Bead M1. Exceeding this amount may lead to some irinotecan remaining free in solution. This free solution should be removed prior to use to prevent the patient receiving the excess dose as a bolus Cautions: Doxorubicin-loaded DC Bead and DC Bead M1 Exceeding a loading dose of 37.5mg doxorubicin per 1ml DC Bead/DC Bead M1 may lead to some systemic distribution of doxorubicin and related side effects Potential Complications: DC Bead and DC Bead M1 Undesirable reflux or passage of DC Bead/DC Bead M1 into normal arteries adjacent to the targeted lesion or through the lesion into other arteries or arterial beds Non-target embolisation Pulmonary embolisation Ischaemia at an undesirable location Capillary bed saturation and tissue damage Ischaemic stroke or ischaemic infarction Vessel or lesion rupture and haemorrhage Neurological deficits including cranial nerve palsies Vasospasm Death Recanalisation Foreign body reactions necessitating medical intervention Infection necessitating medical intervention Clot formation at the tip of the catheter and subsequent dislodgement causing arterial thromboembolic sequelae WARNING: Studies have shown that DC Bead and DC Bead M1 do not form aggregates and, as a result, penetrate deeper into the vasculature as compared to similarly sized PVA particles. Ordering Information: Product Name DC Bead M1 DC Bead Label Colour and Size µm µm µm µm Volume of Beads Product Code DC2V001 DC2V103 DC2V305 DC2V507 For more information, please contact: Biocompatibles UK Limited Chapman House, Farnham Business Park Weydon Lane, Farnham, Surrey, GU9 8QL, UK Tel: +44 (0) Fax: +44 (0) marketing@biocompatibles.com DC Bead, DC Bead M1 and DEBIRI are trademarks of Biocompatibles UK Ltd; DC Bead is a registered trademark in US, EU, China, Japan, South Korea; DEBIRI is a registered trademark in US and EU. Biocompatibles UK Ltd is a BTG International group company. BTG and the BTG roundel are registered trademarks of BTG International Ltd in US, EU and certain other territories and trademarks of BTG International Ltd elsewhere. DC Bead and DC Bead M1 are not currently cleared by the FDA for sale or distribution in the USA. Copyright 2013 Biocompatibles UK Ltd. GxUS-DCB Rev 1. Biocompatibles Excellence in Interventional Oncology Biocompatibles UK Ltd is a BTG International group company
DC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data
DC Bead Chemoembolisation for the Treatment of Primary [DEBDOX ] and Secondary [DEBIRI ] Liver Cancer Review of Published Clinical Data Professor Thomas J Vogl Goethe University Hospital Frankfurt-am-Main,
More informationAintree University Hospital
Aintree University Hospital Liverpool, UK Evolving role of DEBIRI with DC Bead - TACE in mcrc Hassan Z Malik MD FRCS Consultant Hepatobiliary Surgeon Hassan Z Malik is a consultant to Biocompatibles UK
More informationWe don t make DC Bead for just anybody. We make it for you. We make it for your patients. Made to a higher standard. Yours. Imagine where we can go.
We don t make DC Bead for just anybody. We make it for you. We make it for your patients. Imagine where we can go. btg-im.com Only DC Bead is backed by clinical studies and peer-reviewed data in HCC which
More informationRole of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer
Role of loco-regional treatment in the medical and surgical management strategy of metastatic colorectal cancer M Ducreux, MD, PhD Gustave Roussy Villejuif, FRANCE M Ducreux is a consultant to Biocompatibles
More informationINTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES. Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí
INTRAARTERIAL TREATMENT OF COLORECTAL LIVER METASTASES Dr. Joan Falcó Interventional Radiology UDIAT. Hospital Universitari Parc Taulí STRATEGIES FOR CRLM LIVER METASTASES Extended indications Resectable
More informationTips and tricks. Camillo Aliberti, Massimo Tilli
Tips and tricks Camillo Aliberti, Massimo Tilli Unit of Oncological Diagnostic and Interventional Radiology, Delta Hospital AUSL Ferrara, Ferrara Italy camy.ali@libero.it mtilli72@libero.it Intra-arterial
More informationTransarterial Chemoembolisation (TACE) with Drug-Eluting Beads
Transarterial Chemoembolisation (TACE) with Drug-Eluting Beads A minimally invasive treatment for liver cancer Provided as an educational service by Biocompatibles UK Ltd, a BTG International group company
More informationColon Cancer Liver Metastases: Liver-Directed Therapy
Colon Cancer Liver Metastases: Liver-Directed Therapy Shishir K. Maithel, MD FACS Assistant Professor of Surgery Division of Surgical Oncology Winship Cancer Institute Emory University August 10, 2014
More informationTreatment of Colorectal Liver Metastases State of the Art
Treatment of Colorectal Liver Metastases State of the Art Eddie K. Abdalla, MD, FACS Professor and Chairman of Surgery Chief of Hepatobiliary Surgery Hilton Metropolitan Palace Hotel Beirut 16 November,
More informationState of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options
State of the art management of Colorectal Liver Metastasis: an interplay of Chemotherapy and Surgical options Ioannis S. Hatzaras, MD, MPH, FACS Assistant Professor of Surgery Division of Surgical Oncology
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationDC Bead LUMI Radiopaque Embolic Drug-Eluting Bead INSTRUCTIONS FOR USE. STERILE:SINGLE USE ONLY: (Do not use if package is opened or damaged)
UK DC Bead LUMI Radiopaque Embolic Drug-Eluting Bead INSTRUCTIONS FOR USE STERILE:SINGLE USE ONLY: (Do not use if package is opened or damaged) DESCRIPTION: DC Bead LUMI are precisely calibrated, radiopaque,
More informationThe Surgical Management of Colorectal Metastases
11th July 2017 Bowel Cancer UK The Surgical Management of Colorectal Metastases Ben Cresswell MD(Res) FRCS Consultant HPB Surgeon The Basingstoke Hepatobiliary Unit United Kingdom Surgical Management of
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationColorectal Liver Metastases Metachronous
Colorectal Liver Metastases Metachronous Professor Rowan Parks Professor of Surgical Sciences University of Edinburgh No disclosures Natural History of Unresected Untreated Colorectal Metastases Year N
More informationClinical Study Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer
Gastroenterology Research and Practice Volume 5, Article ID 75, 6 pages http://dx.doi.org/.55/5/75 Clinical Study Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationCurrent Treatment of Colorectal Metastases. Dr. Thavanathan Surgical Grand Rounds February 1, 2005
Current Treatment of Colorectal Metastases Dr. Thavanathan Surgical Grand Rounds February 1, 2005 25% will have metastases at initial presentation 25-50% 50% will develop metastases later 40% of potentially
More informationEPIDEMIOLOGY. Long established risk factors for CCA: hepatobiliaryflukes, PSC, biliary tract cysts, epatolithiasis.
EPIDEMIOLOGY Intrahepatic cholangiocarcinoma(icc) is the second most common (15%) primary liver cancer after hepatocellular carcinoma (HCC), with a rate of about 2.1/100,000 people per year in western
More informationLIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE METASTASES
LIVER DIRECTED THERAPIES FOR PATIENTS WITH UNRESECTABLE COLORECTAL CANCER LIVER METASTASES Jaime R. Merchan, MD, MMSc Associate Professor of Medicine Division of Hematology-Oncology University of Miami
More informationResection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy
Resection of liver limited resectable metastases Upfront, neoadjuvant and repeat hepatectomy Dr Chan Chung Yip MBBS, M.Med(Surgery), MD, FAMS, FRCSEd Senior Consultant and Head Department of Hepatopancreatobiliary
More informationhqtace The Next Generation in Liver Cancer Treatment
HepaSphere Microspheres Quality Targeted to the tumor Absorbs drug Conforms to the vessel Elutes and embolizes hqtace The Next Generation in Liver Cancer Treatment Quality TACE hqtace The No-Compromise
More informationSELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER
SELECTIVE INTERNAL RADIATION THERAPY FOR TREATMENT OF LIVER CANCER SIR-Spheres*: A New Treatment Option for Non-Resectable Liver Tumors Treatment Overview SIRT: Selective Internal Radiation Therapy Concept
More informationBehandeling van colorectale levermetastasen. Rol van beeldvorming van de lever bij colorectaal carcinoom
Behandeling van colorectale levermetastasen Rol van beeldvorming van de lever bij colorectaal carcinoom B. Op de Beeck Universitair Ziekenhuis Antwerpen bart.op.de.beeck@uza.be 10.12.2016 AZ Turnhout campus
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationALARA and Radiation Safety
ALARA and Radiation Safety Experience the power of TheraSphere and deliver hope where it s needed most. Imagine where we can go. btg-im.com What is TheraSphere? TheraSphere is indicated for radiation treatment
More informationManagement of Colorectal Liver Metastases
Management of Colorectal Liver Metastases MM Bernon, JEJ Krige HPB Surgical Unit, Groote Schuur Hospital Department of Surgery, University of Cape Town 50% of patients with colorectal cancer develop liver
More informationAcoustic Pulse Thrombolysis Treatment
Acoustic Pulse Thrombolysis Treatment BTGVascular.com SETTING THE STANDARD FOR VASCULAR THERAPIES Quickly & safely dissolve thrombus with the EKOS System. The Acoustic Pulse Difference Acoustic Pulse Thrombolysis
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationProstatic Artery Embolisation
Prostatic Artery Embolisation Results You Can Trust Embosphere Microspheres, the most clinically studied round embolic, provide consistent and predictable results for effective embolisation in the treatment
More informationCOMPARING Y90 DEVICES
COMPARING Y90 DEVICES William S Rilling MD, FSIR Professor of Radiology and Surgery Director, Vascular and Interventional Radiology Medical College of Wisconsin DISCLOSURES Research support : Siemens,
More informationMinimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More informationJose Ramos. Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma
Role of Surgery in isolated hepatic metastasis from breast carcinoma, melanoma or sarcoma Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre Evolution of liver resection Better understanding
More informationEvolution of Surgery: Role of the Surgeon in the Molecular and Technology Age. Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010
Evolution of Surgery: Role of the Surgeon in the Molecular and Technology Age Yuman Fong, MD Memorial Sloan-Kettering Cancer Center Rio 2010 Molecular mechanisms for cancer Prevention and screening Molecular
More informationRuolo della interventistica per le secondarietà epatiche e di altre sedi
Ruolo della interventistica per le secondarietà epatiche e di altre sedi Giancarlo Bizzarri Dipartimento di Diagnostica per Immagini e Radiologia Interventistica Ospedale Regina Apostolorum, Albano Laziale
More informationMinimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go.
ALARA & RADIATION SAFETY Minimizing Unnecessary Radiation Exposure to Healthcare Professionals and Patients Imagine where we can go. What is ALARA? As Low As Reasonably Achievable The use of radiation
More informationIs it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS
Is it possible to cure patients with liver metastases? Taghizadeh Ali MD Oncologist, MUMS Survival Rates of by Stage of Adenocarcinoma of the Colon Liver Resection New Perspective Colorectal cancer liver
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
of the clinical trial data for this outcome. Therefore, perc considered that the cost-effectiveness of cetuximab plus FOLFIRI would be at the higher end of the EGP s range of best estimates. Therefore,
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationMultidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers
Multidisciplinary Treatment Strategies for Primary and Metastatic Liver Cancers Ching-Wei D. Tzeng, M.D. Assistant Professor Surgical Oncology University of Kentucky Markey Cancer Center Affiliate Network
More informationReference: NHS England: 16022/P
Clinical Commissioning Policy: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England: 16022/P
More informationPatient Selection for Drug Eluting Bead Irinotecan (DEBIRI): Surgical Oncologist Perspective
Patient Selection for Drug Eluting Bead Irinotecan (DEBIRI): Surgical Oncologist Perspective Robert Martin, MD, PhD Sam & Lolita Weakley Endowed Chair in Surg Onc Professor of Surgery Director, Division
More informationNHS England. Cedar on behalf of NHS England Specialised Commissioning
NHS England Evidence review: selective internal radiation therapy (SIRT) with ytrrium-90 microspheres for unresectable, liver-only or liver-dominant metastatic colorectal carcinoma who are chemotherapyrefractory
More informationRuby Coil. Large Volume Detachable Coils
Ruby Coil Ruby Case Examples 38 mm Hepatic Artery Aneurysm Pulmonary AVM 2 Coils Dr. James Benenati Miami Cardiac and Vascular Institute, FL Y90 Embolization Type 2 Endoleak Dr. J Moskovitz Florida Hospital,
More informationNCCN TRENDS DEMOGRAPHICS. Results: March 2014 LIVER CANCER. Distribution of Respondent Types (n = 581) Page 1
NCCN TRENDS Results: March 2014 NCCN Trends is an analytics tool from the National Comprehensive Cancer Network (NCCN ) that surveys how clinicians across the U.S. and around the globe are delivering cancer
More informationLocoregional Treatments for HCC Applications in Transplant Candidates. Locoregional Treatments for HCC Applications in Transplant Candidates
Locoregional Treatments for HCC Applications in Transplant Candidates Matthew Casey, MD March 31, 2016 Locoregional Treatments for HCC Applications in Transplant Candidates *No disclosures *Off-label uses
More informationHepatocellular Carcinoma: A major global health problem. David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center
Hepatocellular Carcinoma: A major global health problem David L. Wood, MD Interventional Radiology Banner Good Samaritan Medical Center Hepatocellular Carcinoma WORLDWIDE The #2 Cancer Killer Overall cancer
More informationSUMMARY OF THE SIRFLOX RESULTS
SUMMARY OF THE SIRFLOX RESULTS The SIRFLOX study results on the combination of SIR-Spheres Y-90 resin microspheres with first-line chemotherapy were published in Journal of Oncology in early 2016. 1 There
More informationtreatment options for primary liver malignancies and metastatic disease
State of the art treatment options for primary liver malignancies and metastatic disease Peter Huppert Prof. of Radiology and Neuroradiology Klinikum Darmstadt Certified Vascular and Oncologic Center Disclosure
More informationIntra arterial ports: complex, demanding but rewarding
Intra arterial ports: complex, demanding but rewarding Gregory Amouyal, MD. Marc sapoval, MD. PhD. Olivier Pellerin, MD. MsC. Interventional Radiology Department, hospital European Georges Pompidou, Paris,
More informationSelection Criteria and Insertion of SIRT into HCC Treatment Guidelines
Selection Criteria and Insertion of SIRT into HCC Treatment Guidelines 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore Pierce Chow FRCSE PhD SIRT in
More informationEKOS. Interventional Vascular 3 February, Imagine where we can go.
EKOS Interventional Vascular 3 February, 2015 Imagine where we can go. Forward-looking statement This presentation and information communicated verbally to you may contain certain projections and other
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationVectibix. Vectibix (panitumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.85 Subject: Vectibix Page: 1 of 5 Last Review Date: December 2, 2016 Vectibix Description Vectibix
More informationErbitux. Erbitux (cetuximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.84 Subject: Erbitux Page: 1 of 6 Last Review Date: December 2, 2016 Erbitux Description Erbitux (cetuximab)
More informationReference: NHS England B01X26
Clinical Commissioning Policy Proposition: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England
More informationKEYWORDS: hepatic artery therapy, irinotecan, liver-directed therapy, liver-dominant metastatic colorectal cancer, metastatic colon cancer.
Randomized Controlled Trial of Irinotecan Drug-Eluting Beads With Simultaneous FOLFOX and Bevacizumab for Patients With Unresectable Colorectal Liver-Limited Metastasis Robert C. G. Martin II, MD, PhD
More informationBevacizumab 5mg/kg Therapy 14 days
INDICATIONS FOR USE: Bevacizumab 5mg/kg Therapy 14 days Regimen Code 00211a *Reimbursement status Hospital INDICATION ICD10 In combination with fluoropyrimidine-based chemotherapy C18 for treatment of
More informationHow to deal with synchronous primary and liver metastases
How to deal with synchronous primary and liver metastases Luis Sabater Ortí MD, PhD Associate Professor University of Valencia European Board Surgical Qualification HBP (EBSQ-HPB) Department of Surgery.
More informationHepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization
Hepatic metastases of neuroendocrine tumors: treatment options and outcomes of local patients treated with radioembolization JP King PGY2 May 22, 2015 Neuroendocrine Tumor (NET) WHO Classification Location
More information4th ESSO Advanced Course on the Management of Colorectal Liver Metastases
4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 10-11 October 2016 BORDEAUX (FR) 4 th ESSO Advanced Course on the Management of Colorectal Liver Metastases Chairs Serge Evrard,
More informationTrattamento chirurgico delle lesioni epatiche secondarie difficili. Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica
Trattamento chirurgico delle lesioni epatiche secondarie difficili Adelmo Antonucci Chirurgia Oncologica e Epato-bilio-pancreatica What does it mean difficult lesions? Diagnosis Treatment Small size Unfit
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationRADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE. clic per modificare lo stile del sottotitolo dello schem
XII Congresso Nazionale AIMN 2015 16-19 Aprile 2015 Rimini RADIOEMBOLIZZAZIONE NEI TUMORI EPATICI: STATO DELL ARTE clic per modificare lo stile del sottotitolo dello schem Marco Maccauro Nuclear Medicine
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationChemosaturation: Indication, Technique and Outcome
Chemosaturation: Indication, Technique and Outcome Thomas J Vogl, S Koch, B Gebauer, W Willinek, C Engelke, R Bruening, F Wacker, A Enk I D I R: Institute of Diagnostic and Interventional Radiology Goethe
More informationAXS Catalyst Distal Access Catheter
AXS Catalyst Distal Access Catheter Directions for Use 2 AXS Catalyst Distal Access Catheter ONLY Caution: Federal Law (USA) restricts this device to sale by or on the order of a physician. warning Contents
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationManagement of Stage IV Colorectal Cancer: Expanding the Horizon
Management of Stage IV Colorectal Cancer: Expanding the Horizon May Tee, MD, MPH and Jan Franko, MD, PhD MercyOne Surgical Group (Mercy Surgical Affiliates) GI Oncology Conference 2019 March 1, 2019 Disclosures
More informationTechniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D.
Techniques to Improve Resectability of Colorectal Liver Metastases Ching-Wei D. Tzeng, M.D. Department of Surgery Grand Rounds University of Kentucky January 15, 2014 Metastatic Colorectal Cancer (CRC)
More informationAvastin Sample Coding
First- and Second-line Metastatic Colorectal Cancer C18.0 Malignant neoplasm of the cecum C18.1 Malignant neoplasm of appendix C18.2-C18.9 C19 C20 C21.8 Malignant neoplasm of the colon, various sites Malignant
More informationSirtex Medical Limited (ASX:SRX)
Sirtex Medical Limited (ASX:SRX) Macquarie Australia Conference Mr Gilman Wong, CEO Dr David Cade, CMO Sydney, 8 th May 2014 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd 1 Understanding
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationSystem.
System www.penumbrainc.com POD System Case Examples 45 cm of POD Packing Coil in 1.5 to 3 mm diameter dilating vessel Bronchial Artery Embolization Dr. Amit Kakkar and Dr. Aksim Rivera, Bronx, NY Inflow:
More informationOPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER
OPTIMISING OUTCOMES FOR PATIENTS WITH ADVANCED COLORECTAL CANCER E-Learning Module Stavros Gkolfinopoulos 1, Demetris Papamichael 1, George Pentheroudakis 2 1. Cyprus Oncology Centre, Nicosia, Cyprus 2.
More informationGuidelines for SIRT in HCC An Evolution
Guidelines for SIRT in HCC An Evolution 2 nd Asia Pacific Symposium on Liver- Directed Y-90 Microspheres Therapy 1st November 2014, Singapore The challenge of HCC Surgery is potentially curative in early
More information100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days
100% pure beta emitter Decays to zirconium-90 Physical half-life of 64.1 hours (2.67 days) 94% of radiation delivered within 11 days TheraSphere [US package insert]. Surrey, UK: Biocompatibles UK Ltd,
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationOVERALL CLINICAL BENEFIT
cetuximab plus FOLFIRI to convert unresectable liver metastatses to resectable, perc confirmed that neither the FIRE-3 study nor the CRYSTAL study were designed to assess resectability and, in the absence
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationThe NIHCE guidelines for the management of colorectal cancer
The NIHCE guidelines for the management of colorectal cancer Graeme Poston Chair Colorectal Cancer Guideline Development Group and Colorectal Cancer Quality Standards Committee National Institute of Health
More informationFor personal use only
Sirtex Medical Limited (ASX:SRX) Macquarie Inaugural Annual Emerging Healthcare Conference Mr Gilman Wong, CEO Mr Darren Smith, CFO Dr David Cade, CMO Wednesday, 10 October 2012 Macquarie Securities Group
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationEXPERIENCE MAGIC IN ITS TOUCH MAGIC TOUCH
EXPERIENCE MAGIC IN ITS TOUCH MAGIC TOUCH THE WORLD S FIRST SIROLIMUS COATED BALLOON NANOLUTE TM COATING FORMULATION Nanolute Technology - a Nanocarrier based Drug Delivery Technology specifically designed
More informationIntroduction. Case Report
Case Report A patient who showed a pathologically complete response after undergoing treatment with XELOX plus bevacizumab for synchronous liver metastasis of grade H2 from sigmoid colon cancer Yasuhito
More informationWHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC?
WHAT IS THE BEST APPROACH FOR TRANS-ARTERIAL THERAPY IN HCC? Dr. Alexander Kim Chief, Vascular and Interventional Radiology, Medstar Georgetown University Hospital, USA DISCLAIMER Please note: The views
More informationRegional Therapy for Metastatic Neuroendocrine Tumors. Janette Durham, MD Professor of Radiology University of Colorado School of Medicine
Regional Therapy for Metastatic Neuroendocrine Tumors Janette Durham, MD Professor of Radiology University of Colorado School of Medicine Introduce regional therapy for mnet Arterial therapies Injection
More informationDecember 12 th 2017 CM) INTERVENTIONAL ONCOLOGY 09:00 REGISTRATION
December 12 th 2017 09:00 REGISTRATION 09:30 10:30 LYMPHONODES AND ADRENAL METASTASES Lymphonodes metastases clinical assessment Lymphonodes metastases imaging assessment and percutaneous treatments Adrenal
More information4th ESSO Advanced Course on the Management of Colorectal Liver Metastases
4th ESSO Advanced Course on the Management of Colorectal Liver Metastases 10-11 October 2016 BORDEAUX (FR) 4 th ESSO Advanced Course on the Management of Colorectal Liver Metastases Chairs Serge Evrard,
More informationSIR-Spheres: Des essais cliniques à la pratique courante
SIR-Spheres: Des essais cliniques à la pratique courante Un focus sur le traitement du mcrc en échappement thérapeutique Dr. Michaël Vouche, MD. PhD. Université Libre de Bruxelles Institut Jules Bordet
More informationLiver Directed Therapy for Hepatocellular Carcinoma
Liver Directed Therapy for Hepatocellular Carcinoma Anil K Pillai MD, FRCR, Associate Professor, Department of Radiology UT Houston Health Science Center, Houston, TX, United States. Hepatocellular cancer
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Avastin (bevacizumab) Policy Number: MP-030-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationPredictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy
Original Article Predictors of a True Complete Response Among Disappearing Liver Metastases From Colorectal Cancer After Chemotherapy Rebecca C. Auer, MD 1 ; Rebekah R. White, MD 2 ; Nancy E. Kemeny, MD
More informationSIRT Dosimetry: Sometimes Less Is More
SIRT Dosimetry: Sometimes Less Is More Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director, Radiation Oncology,
More informationStrategy for the treatment of metastatic CRC through the lines
Strategy for the treatment of metastatic CRC through the lines I Congresso de Oncologia D Or 2013: Satellite Symposium, ROCHE David Cosgrove, MD Johns Hopkins University Disclosures No relevant financial
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationIntra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization
Intra-arterial Therapy in Management of HCC: ctace, DEB-TACE, and Y90 Radioembolization Department of Radiology, National Cancer Center In Joon Lee Contents Conventional TACE Role of TACE in management
More information